50 results on '"Blum, S.I."'
Search Results
2. OA14.03 Six-year Survival and HRQoL Outcomes with 1L Nivolumab + Ipilimumab in Patients with Metastatic NSCLC from CheckMate227
3. P2.06-09 Association of Clinical Response and HRQoL with Long-Term Survival with 1L Nivolumab + Ipilimumab in mNSCLC in CheckMate 227
4. PPD04.02 First-Line Nivolumab + Ipilimumab (NIVO+IPI) in Metastatic NSCLC: 5-Year Survival in CheckMate 227
5. 932MO Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) versus chemo as neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC): Health-related quality of life (HRQoL) outcomes from CheckMate 816
6. 1458P Association between health-related quality of life (HRQoL) and clinical outcomes in patients with advanced first-line (1L) renal cell carcinoma (aRCC): Exploratory analyses from CheckMate 9ER (CM 9ER)
7. 668P Matching-adjusted indirect comparison (MAIC) of health-related quality of life (HRQoL) of nivolumab plus cabozantinib (N+C) vs pembrolizumab plus axitinib (P+A) in previously untreated advanced renal cell carcinoma (aRCC)
8. 437P Quality of life (QoL) in patients (pts) with microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) alone or in combination with ipilimumab (IPI): CheckMate 142
9. First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1
10. LBA59 First-line nivolumab (NIVO) + ipilimumab (IPI) combined with 2 cycles of platinum-based chemotherapy (chemo) vs 4 cycles of chemo in advanced non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from CheckMate 9LA
11. Impacts of Lower Back Pain: Refinement of the Pain Assessment for Lower Back-Impacts Questionnaire (Pal-I) Using a Mixed Methods Approach
12. The Pain Assessment for Lower Back Symptoms (Pal-S): Refinement of A New Pro Instrument Through A Mixed Methods Approach
13. The Diabetic Peripheral Neuropathic Pain Impact (DPNPI) Measure – Psychometric Validation of a New Patient Reported Outcome Measure
14. Responder Analysis of Functional Health and Well-Being in MDD: A Pooled Analysis of SF-36 Results from Three Phase III Trials with Levomilnacipran SR
15. The pain assessment for lower back symptoms (PAL-S): Qualitative development and cognitive evaluation of a new patient reported outcome measure for the assessment of low back pain
16. The Pain Assessment For Lower Back Impacts (PAL-I): Qualitative Development And Cognitive Evaluation Of A New Patient Reported Outcome Measure For The Assessment Of Impacts Of Low Back Pain
17. Assessment Of Practice Patterns And Treatment-Failure Medical Costs Among Patients With Chronic Constipation: Findings From A Physician Survey Study
18. Cost-Effectiveness Of Linaclotide For The Treatment Of Adult Patients In The Us With Irritable Bowel Syndrome With Constipation
19. Budgetary Impact Of Linaclotide In The Treatment Of Us Adult Patients With Irritable Bowel Syndrome With Constipation (Ibs-C) Or Chronic Constipation (Cc)
20. Qualitative development and cognitive evaluation of the symptoms of major depressive disorder (s-mdd), a consortium-developed patient reported outcome measure
21. Sustained improvement in functional health and well-being in MDD patients following long-term treatment with Levomilnacipran SR
22. PGI30 Assessment of Practice Patterns and Treatment-Failure Costs Among Patients With Irritable Bowel Syndrome With Constipation: Findings From a Physician Survey Study
23. PMH39 Identifying Disease-Defining Concepts Using Spontaneous and Probed Responses From Semi-Structured Qualitative Interviews in Patients With Major Depressive Disorder
24. PSY38 Spontaneous and Probed Disease-Defining Concepts Identified Through Concept Elicitation Interviews in Chronic Low Back Pain
25. PMH40 How do Patients Describe Their Depression? - Incorporating the Patient's Voice Into Instrument Development
26. PSY35 Assessment of the Most Bothersome Symptoms and Impacts Reported by Patients With Chronic Low Back Pain
27. PMH52 Levomilnacipran in the Treatment of Major Depressive Disorder: Functional Health and Well-Being Efficacy Results from a Phase III Clinical Trial
28. PSY41 Evaluating the Frequency and Sequence of Items Administered Using Promis Computer Adaptive Testing
29. PSY34 CALCULATING PROMIS FATIGUE ITEM BANK IRT PARAMETER ESTIMATES SPECIFIC TO PATIENTS WITH FIBROMYALGIA
30. PSY33 EXPLORING THE FACTOR STRUCTURE OF THE PROMIS FATIGUE ITEM BANK IN PATIENTS WITH FIBROMYALGIA
31. PSY83 - Impacts of Lower Back Pain: Refinement of the Pain Assessment for Lower Back-Impacts Questionnaire (Pal-I) Using a Mixed Methods Approach
32. PSY82 - The Pain Assessment for Lower Back Symptoms (Pal-S): Refinement of A New Pro Instrument Through A Mixed Methods Approach
33. PMH6 - Responder Analysis of Functional Health and Well-Being in MDD: A Pooled Analysis of SF-36 Results from Three Phase III Trials with Levomilnacipran SR
34. PDB87 - The Diabetic Peripheral Neuropathic Pain Impact (DPNPI) Measure – Psychometric Validation of a New Patient Reported Outcome Measure
35. PMH46 - Qualitative development and cognitive evaluation of the symptoms of major depressive disorder (s-mdd), a consortium-developed patient reported outcome measure
36. PMH7 - Sustained improvement in functional health and well-being in MDD patients following long-term treatment with Levomilnacipran SR
37. PGI20 - Assessment Of Practice Patterns And Treatment-Failure Medical Costs Among Patients With Chronic Constipation: Findings From A Physician Survey Study
38. PGI12 - Cost-Effectiveness Of Linaclotide For The Treatment Of Adult Patients In The Us With Irritable Bowel Syndrome With Constipation
39. PGI6 - Budgetary Impact Of Linaclotide In The Treatment Of Us Adult Patients With Irritable Bowel Syndrome With Constipation (Ibs-C) Or Chronic Constipation (Cc)
40. PRM173 - The pain assessment for lower back symptoms (PAL-S): Qualitative development and cognitive evaluation of a new patient reported outcome measure for the assessment of low back pain
41. PO3 - The Pain Assessment For Lower Back Impacts (PAL-I): Qualitative Development And Cognitive Evaluation Of A New Patient Reported Outcome Measure For The Assessment Of Impacts Of Low Back Pain
42. PMH7 Sustained improvement in functional health and well-being in MDD patients following long-term treatment with Levomilnacipran SR
43. PMH6 Responder Analysis of Functional Health and Well-Being in MDD: A Pooled Analysis of SF-36 Results from Three Phase III Trials with Levomilnacipran SR
44. PRM173 The pain assessment for lower back symptoms (PAL-S): Qualitative development and cognitive evaluation of a new patient reported outcome measure for the assessment of low back pain
45. PDB87 The Diabetic Peripheral Neuropathic Pain Impact (DPNPI) Measure – Psychometric Validation of a New Patient Reported Outcome Measure
46. PGI6 Budgetary Impact Of Linaclotide In The Treatment Of Us Adult Patients With Irritable Bowel Syndrome With Constipation (Ibs-C) Or Chronic Constipation (Cc)
47. PO3 The Pain Assessment For Lower Back Impacts (PAL-I): Qualitative Development And Cognitive Evaluation Of A New Patient Reported Outcome Measure For The Assessment Of Impacts Of Low Back Pain
48. PMH46 Qualitative development and cognitive evaluation of the symptoms of major depressive disorder (s-mdd), a consortium-developed patient reported outcome measure
49. 2O Health-related quality of life (HRQoL) with first-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW
50. 399P A Quality-adjusted Time Without Symptoms and Toxicity (Q-TWiST) analysis comparing nivolumab plus chemotherapy (N+CT) or nivolumab plus ipilimumab (N+I) vs CT in patients (pts) with tumor cell PD-L1 ≥ 1% advanced esophageal squamous cell carcinoma (ESCC): CheckMate 648
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.